Fjarde AP Fonden Fourth Swedish National Pension Fund Purchases 1,200 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 52.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,480 shares of the medical research company's stock after acquiring an additional 1,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Bio-Rad Laboratories were worth $1,143,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Strategic Financial Concepts LLC bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at $3,561,000. Lecap Asset Management Ltd. purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth about $510,000. Principal Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock worth $14,836,000 after purchasing an additional 21,669 shares in the last quarter. Mawer Investment Management Ltd. grew its stake in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock valued at $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC lifted its position in Bio-Rad Laboratories by 193.3% during the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company's stock valued at $1,161,000 after purchasing an additional 2,287 shares during the last quarter. 65.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Finally, StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $395.20.

Bio-Rad Laboratories Trading Down 0.4 %

Bio-Rad Laboratories stock traded down $1.03 during mid-day trading on Friday, reaching $264.60. 301,776 shares of the company traded hands, compared to its average volume of 231,866. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The firm's 50 day moving average price is $327.02 and its 200 day moving average price is $332.57. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of -4.07 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 52-week low of $262.11 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.